Airdoc

Airdoc was founded in September 2015 and is committed to providing comprehensive and multi-faceted artificial intelligence solutions for the early detection, auxiliary diagnosis, and health risk assessment of chronic diseases. It is a global leader and pioneer in the field of artificial intelligence for retinal imaging. On November 5, 2021, Airdoc successfully listed on the Hong Kong Stock Exchange, with the stock code 02251.HK, becoming the "first medical AI stock." Airdoc's diabetic retinopathy auxiliary diagnostic software was the first among similar products to obtain the National Medical Products Administration's Class III medical device certificate and has been implemented in medical institutions to assist doctors in making medical diagnoses. To address unmet healthcare needs, the company has developed a rich pipeline of products related to artificial intelligence retinal imaging, which are widely used in community clinics, physical examination centers, insurance companies, optometry centers, and pharmacies to provide users with disease auxiliary diagnosis and health risk assessment. Airdoc is headquartered in Beijing and has established subsidiaries and R&D centers in Beijing, Shanghai, Guangzhou, Shenzhen, and Hong Kong, with offices in Nanjing, Xi'an, Chengdu, and Wuhan. In recognition of its technological advantages and social value in the medical and technology fields, Airdoc has received honors such as the "Wu Wenjun Artificial Intelligence Science and Technology Progress Award," the highest award in China's artificial intelligence field. Adhering to the corporate mission of "making health accessible everywhere," Airdoc will collaborate with a wide range of partners to make high-quality healthcare services as readily available as air—anytime, anywhere, within reach.